Jacobs Levy Equity Management Inc. Purchases Shares of 26,900 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Jacobs Levy Equity Management Inc. acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 26,900 shares of the medical equipment provider’s stock, valued at approximately $2,406,000.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. grew its stake in Lantheus by 52.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 25,936 shares of the medical equipment provider’s stock valued at $2,320,000 after buying an additional 8,959 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in shares of Lantheus by 26.4% during the fourth quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider’s stock worth $220,000 after acquiring an additional 513 shares during the period. Empirical Asset Management LLC acquired a new position in shares of Lantheus in the fourth quarter valued at approximately $323,000. Procyon Advisors LLC increased its stake in shares of Lantheus by 11.1% during the fourth quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider’s stock worth $323,000 after purchasing an additional 361 shares during the period. Finally, Shelton Wealth Management LLC lifted its holdings in Lantheus by 77.8% during the 4th quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider’s stock worth $1,071,000 after purchasing an additional 5,237 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,109 shares of company stock worth $6,016,046. Insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.2%

LNTH stock opened at $79.78 on Friday. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89. The business has a 50-day simple moving average of $97.57 and a 200 day simple moving average of $93.51. The company has a market cap of $5.46 billion, a PE ratio of 13.27 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus’s quarterly revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.69 earnings per share. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on LNTH. B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Truist Financial dropped their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus has a consensus rating of “Buy” and an average price target of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.